Navigation Links
AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Date:6/10/2009

QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the opening of an extended study in the Phase 3 program with cetrorelix pamoate for the treatment of benign prostatic hyperplasia (BPH), a benign enlargement of the prostate, affecting more than 20 million men in the U.S. alone. Sanofi-aventis U.S. LLC entered into a previously announced agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

As a result of this collaboration between sanofi-aventis U.S. and AEterna Zentaris, patients completing two years of therapy in the North American trial of cetrorelix, NCT00449150, will be eligible to continue with cetrorelix treatment, according to treatment regimen of the ongoing Phase 3 study, until the end of 2011. Patients entering this extension study will be followed-up for safety, International Prostate Symptom Score (IPSS) and quality of life during the extended treatment, providing follow-up data on cetrorelix for up to 5 years.

Juergen Engel, Ph.D., President and CEO of AEterna Zentaris commented, "We have been pleased with the decision of patients and their physicians to continue into this extended period of open-label treatment follow-up, sponsored by our partner sanofi-aventis U.S. We are confident that patients and their physicians will continue into this extension, as the continuation rate of patients into the open-label part of the study remains at over 90% of those eligible to continue at week 52 and compares favorably with those reported by others.(1) We look forward to presenting the data from the double-blind portion of the study in the next quarter."

About the Phase 3 Program with Cetrorelix in BPH

Cetrorel
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
2. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
3. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
4. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
5. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
6. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
7. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
8. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
9. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
10. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
11. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- , Not for release, publication or distribution ... jurisdiction where to do so would constitute a violation of ... ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG ... has held a meeting with representatives of AbbVie. ... agreement or approval of AbbVie. A further update ...
(Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... 10, 2014 EvoDerma ’s NOOME Anti-Aging ... rejuvenating device now comes with a second treatment cup to ... , The new cup is thinner on the edges for ... target rough, thin and uneven surfaces on the face, neck ... a stimulating treatment on areas such as the cheeks and ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... venture investors have fewer secrets these days, and they ... early-stage executives during the National SBIR-STTR Conference. , ,In ... the University of Wisconsin-Madison , they counseled technology ... sustainable market advantage, and what each round of funding ...
... - Quintessence Biosciences , a biopharmaceutical company ... its EVade cancer treatments, has been selected for preclinical ... that pending a favorable preclinical safety assessment, it would ... an investigational new drug application in late 2007, ...
... Milwaukee, Wis. - The University of Wisconsin-Milwaukee ... for its incorporation of a content storage and collaboration ... , ,The PantherFile system, powered by Xythos Software ... 100, a group of organizations that invest in innovative ...
Cached Biology Technology:Early-stage executives hear from investors 2Early-stage executives hear from investors 3
(Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
(Date:7/10/2014)... July 3, 2014 Research and Markets ... the "Global Gesture Recognition & Touch-Less Sensing ... to 2020" report to their offering ... Gesture Recognition & Touch-Less Sensing Market to Grow ... a while, but the companies were unable to ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... Mich.---A new synthetic Petri dish coating could overcome a ... cell research, say University of Michigan researchers. Under ... yielding human therapies because the cells have been grown ... "These nondefined, animal-based components create issues with the ...
... economic stimulus program (ARRA) Health Information Technology for Economic ... of health information technology (HIT) and to ready a ... members of the American Medical Informatics Association (AMIA), a ... has advocated for informatics as a health care specialty. ...
... Troy, N.Y. Patrick Underhill, assistant professor in ... Rensselaer Polytechnic Institute, has won a prestigious Faculty ... Science Foundation (NSF). Underhill will use ... into how transport phenomena affect biological processes. He ...
Cached Biology News:New culture dish could advance human embryonic stem cell research 2AMIA Members Manage HITECH Stimulus Grant Awards 2Rensselaer Polytechnic Institute professor Patrick Underhill receives NSF CAREER award 2
... Automatic grid, subgrid and spot finding overcome tedious spot, ... template assignment , ... options to optimize, ... Characterize more precisely through grouping by cells, grids, ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
... liter of urine will give a positive reaction ... ,Certification: The Donors are of US origin ... NEGATIVE for HbsAg, HCV, HIV-1 & 2, Syphilis ... THIS MATERIAL IS SOLD FOR IN-VITRO DIAGNOSTIC USE ...
Biology Products: